Podcast appearances and mentions of Jonathan W Goldman

In today's episode, we spoke with Jonathan W. Goldman, MD, about the phase 2 LUMINOSITY study (NCT03539536) evaluating telisotuzumab vedotin-tllv (Teliso-V; Emrelis) in patients with c-MET protein–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). Dr Goldman is a professor of medicine in the Division of Hematology/Oncology at UCLA, as well as director of Clinical Trials in Thoracic Oncology, associate director of Early Drug Development, and chair of the University of California Lung Cancer Consortium.

Featuring an interview with Dr Jonathan W Goldman, including the following topics: Contemporary and Future Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation (0:00) Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation (21:05) Other Emerging Strategies for Relapsed Metastatic Lung Cancer (29:16) Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation (37:59) Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation (45:29) CME information and select publications

Dr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation.

Dr Jonathan W Goldman from UCLA Health in Santa Monica, California, summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayASCOEGFRNSCLC24).

Featuring perspectives from Dr Jonathan W Goldman, Dr Corey J Langer, Dr Joel W Neal, Dr Zofia Piotrowska, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics: Introduction (0:00) Contemporary Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Langer (2:08) Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation — Dr Goldman (22:37) Biological Rationale for and Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation — Dr Yu (43:23) Other Emerging Strategies for Relapsed Metastatic NSCLC with an EGFR Mutation — Dr Sabari (1:03:33) Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation — Dr Piotrowska (1:20:15) Management of Toxicities Associated with Available and Emerging Therapies for NSCLC with an EGFR Mutation — Dr Neal (1:38:44) CME information and select publications

Jonathan W. Goldman, MD - Don't Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

Jonathan W. Goldman, MD - Don't Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

Jonathan W. Goldman, MD - Don't Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

Jonathan W. Goldman, MD - Don't Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

Jonathan W. Goldman, MD - Don't Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

Jonathan W. Goldman, MD - Don't Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.